the Activating Consciousness Technique (Hypnosis) in General Practice
MG HYPNOSIS
Evaluation of the Activating Consciousness Technique (Hypnosis) in Anxiety in a General Practice
1 other identifier
observational
200
1 country
6
Brief Summary
Anxiety is an emotion considered unpleasant but resulting from a normal phenomenon. It corresponds to an adaptive response to events, to stress and helps to ensure our survival. On the other hand, it becomes embarrassing when it becomes uncontrollable. It can even lead to interfere with activities of daily living. Thus, we can speak of anxiety disorder. Anxiety disorders are among the most prevalent psychiatric disorders. They are often associated with other comorbidities such as depression, which makes them more difficult to treat and diagnose. Different treatments are offered to best treat the patient with anxiety : drug treatment (antidepressants, anxiolytics) ; non-drug (psychotherapy, meditation, cognitive behavioral therapies). The emergence of hypnosis in medical practice in recent years seems to be a technique that can bring benefits to the patient. A review of clinical studies does not seem to find a benefit to hypnosis in anxiety disorders. In contrast, a study in children with school phobia showed the effectiveness of hypnosis. The limits addressed by this review seem to relate to the number of people included in the studies. Contrariwise, it has been pointed out that hypnosis can have a beneficial effect in the long term. Thus, it seems interesting to deepen this technique in the practice of a general practitioner exercising the activating consciousness technique in anxiety. The study will be composed of patients presenting with anxiety and consulting their general practitioner, with: Group 1, patients consulting a doctor not practicing hypnosis Versus Group 2, patients consulting a doctor practicing hypnosis. During the first consultation and the following 2 consultations scheduled by the general practitioner (spaced 15 days apart), the following data are noted, in addition to the monitoring usually performed by the doctor:
- 1.COVI scale
- 2.Comfort scale 0 to 10
- 3.Management: drugs, TAC, others
- 4.Quality of life survey SF36 Patients will be called back at 6 months to reassess quality of life (self-administered survey SF 36) The primary endpoint is to evaluated the change of anxiety from inclusion (J0) to 6 months using COVI scale in the two different groups.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2020
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 29, 2020
CompletedStudy Start
First participant enrolled
October 1, 2020
CompletedFirst Posted
Study publicly available on registry
December 2, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2022
CompletedDecember 2, 2020
December 1, 2020
2 years
September 29, 2020
December 1, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change of the score of anxiety from inclusion (J0) to 6 months evaluated byvia COVI scale
COVI scale (questionnaire completed by patients) is a scale that permits to evaluate the clinical anxiety. The range is 0-100. The higher the score, the more the anxiety. The clinical cut-off score is 30.
6 months
Study Arms (2)
Control
Group 1 includes patients with anxiety consulting a doctor not practicing hypnosis
TAC
Group 2 includes patients with anxiety consulting a doctor practicing hypnosis
Interventions
activating consciousness technique (hypnosis)
Eligibility Criteria
Patient with anxiety according to DSM V-C criteria: 3 of 6 symptoms * Agitation or sensation of being overflown or exhausted * Fatigability * Difficulty concentrating or memory lapses * Irritability * Muscle tension
You may qualify if:
- Male or Female over 18
- Anxiety patient
- Patient who can return for consultation regularly and can be reached by phone
- Patient Not Opposing Participation In Study
You may not qualify if:
- \- Follow-up deemed impossible by the investigator
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (6)
Dr Stéphane FOLACHER
Bourg-en-Bresse, 01000, France
Dr Céline HUMBERT
Lyon, 69008, France
Dr Matthieu DEMOURGUES
Lyon, 69008, France
Dr Christian SAINT-CYR
Saint-Étienne-du-Bois, 01370, France
Dr Aurélien BARADEL
Saint-Martin-du-Frêne, 01430, France
Dr Maud BINARD
Villereversure, 01250, France
Related Publications (1)
Pelissolo A. [Hypnosis for anxiety and phobic disorders: A review of clinical studies]. Presse Med. 2016 Mar;45(3):284-90. doi: 10.1016/j.lpm.2015.12.002. Epub 2016 Mar 2. French.
PMID: 26944812BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 29, 2020
First Posted
December 2, 2020
Study Start
October 1, 2020
Primary Completion
October 1, 2022
Study Completion
October 1, 2022
Last Updated
December 2, 2020
Record last verified: 2020-12
Data Sharing
- IPD Sharing
- Will not share